Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.65 |
| ▸ | HTR2A | P28223 | 15/20 | 0.65 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6197170 | 0.99 | HTR2C (0.64) | HTR2CHTR2AHTR2BNFKB1MAOA | |
| SCHEMBL6194351 | 0.85 | HTR2C (0.61) | HTR2CHTR2AHTR2BNFKB1MAOA | |
| SCHEMBL6195477 | 0.81 | HTR2C (0.57) | HTR2CHTR2AHTR2BADORA2A | |
| SCHEMBL6199931 | 0.79 | HTR2C (0.61) | HTR2CHTR2AHTR2BNFKB1MAOA | |
| Hydrochloric Acid SCHEMBL6195672 | 0.79 | HTR2C (0.64) | HTR2CHTR2AHTR2BNFKB1MAOA | |
| SCHEMBL905958 | 0.79 | HTR2C (1.00) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL6196249 | 0.78 | HTR2C (0.97) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL6198656 | 0.78 | HTR2C (0.97) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL6198201 | 0.78 | HTR2C (0.97) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL6195270 | 0.78 | HTR2A (0.43) | HTR2CHTR2AHTR2BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0990650-B1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | claimed |
| US-6245796-B1 | NERVOUS SYSTEM DISORDERS; SEXUAL DISORDERS; SLEEP DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | claimed |
| EP-0990650-A1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-04-05 | — | — | EP | claimed |
| CN-113024399-B | Pharmaceutical intermediate compound and preparation method and application thereof | 华东理工大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-113024399-A | Pharmaceutical intermediate compound and preparation method and application thereof | 华东理工大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-113024469-A | Synthesis method of telmisartan intermediate | 华东理工大学 | 2021-06-25 | — | — | CN | disclosed |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. | 2013-10-10 | — | — | US | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| US-7476687-B2 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2009-01-13 | — | — | US | disclosed |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2009-01-08 | — | — | US | disclosed |
| EP-0990650-B1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005053688-A1 | SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-6881749-B2 | Pyranoindazoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-19 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | disclosed |
| US-6696476-B2 | SUCH AS 1-(2-AMINOPROPYL)-1,7,8,9-TETRAHYDRO-PYRANO(2,3-G)-INDAZOL-8-OL; LOWERING AND CONTROLLING INTRAOCULAR PRESSURE | ALCON, INC. (CH) | 2004-02-24 | — | — | US | disclosed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
| US-6245796-B1 | NERVOUS SYSTEM DISORDERS; SEXUAL DISORDERS; SLEEP DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0990650-A1 | TRICYCLIC PYRROLE OR PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | PDE3A, CYP11B2, PDE3B | HTR2C 2288/4885HTR2A 2774/4885HTR2B 2644/4885 |
| US-20030171418-A1 | Reducing or controlling eye pressure | PDE3A, PDE3B, QDPR | HTR2C 1978/4885HTR2A 1849/4885HTR2B 1919/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR2B 10/4885 |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ADRA2C, HTR2C, HTR2A | HTR2C 2/4885HTR2A 3/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.